Clinical trials: Type 2 Inflammatory Disorders
Colitis, Ulcerative
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
This is a study to understand if taking VTX002 daily as a tablet orally is safe and effective in participants diagnosed with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05156125
- Testing
- VTX002
- Where
- 77 sites in United States, Bulgaria and 12 more
- Volunteers
- 213 people
- Sponsor
- Oppilan Pharma Ltd
Type2 Diabetes, Coronary Artery Disease
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Epicardial adipose tissue (EAT) is the visceral fat of the heart. EAT could locally affect the coronary arteries through local secretion of pro-inflammatory cytokines.
- Trial name
- NCT03260881
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Type 2 Diabetes Mellitus, Insulin Resistance
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D.
- Trial name
- NCT02597101
- Testing
- Metformin, saxagliptin, AZD9668
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nick Giannoukakis, PhD
Dermatitis, Atopic, Dermatitis
Effect of Benralizumab in Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a common skin disease characterized by itchy lesions. The prevalence of AD has increased over the past few decades, with 15-30% of children and 2-10%of adults being affected.
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- NCT03563066
- Testing
- Benralizumab
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- McMaster University
Type 2 Diabetes Mellitus, Cognitive Impairment
Intensive Aerobic and Resistance Exercise Program (IAREP)
A 12-week Intensive Aerobic and Resistance Exercise Program (IAREP) intervention was implemented on high-risk and low-risk subjects with cognitive impairment in type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes Mellitus, Cognitive Impairment, Non-insulin-dependent Diabetes Mellitus, Cognitive Dysfunction
- Trial name
- NCT06401733
- Testing
- Intensive Aerobic and Resistance Exercise Program (IAREP)
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University of Singapore
Type 2 Diabetes Mellitus
Sitagliptin Therapy and Kinetics of Inflammatory Markers
Inflammatory processes are increasingly being recognized as a critical step in the pathogenesis of both diabetes and heart disease and may constitute a biological link between the two diseases.
- Trial name
- NCT02536248
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Laval University